Letters to the Editor

Clinical pharmacology and therapeutics

Sir,
I am writing with regard to the recent Reviews in Medicine article ‘Clinical pharmacology and therapeutics’ by M.J. Kendall and R.C. Horton.1

Several points are made in the section ‘Peculiar ulcer disease’ (p. 174) about the prostaglandin analogue misoprostol (note correct spelling) which do not accurately reflect the available data.

The authors incorrectly state that misoprostol does not prevent non-steroidal anti-inflammatory drug (NSAID)–induced duodenal lesions. Several studies have shown its efficacy both in the prevention2–6 and healing7,8 of NSAID-induced duodenal lesions. It is important to note, as the authors correctly do, that NSAID-induced damage has been shown in most studies to be predominant gastric. Thus from the clinician’s viewpoint when prescribing an agent to protect against NSAID-induced damage it is important to use an agent such as misoprostol which will prevent both gastric and duodenal damage.

The authors also incorrectly state that misoprostol is no better than placebo at preventing pain. Several studies have demonstrated that misoprostol is superior to placebo.9–11

The authors state that ‘how one identifies this population’ (of patients likely to develop complications) is at present unknown. In fact there are now considerable data indicating various groups of patients who are at increased risk of developing complications if they take NSAIDs. Two large studies, one from the US12 and one from Great Britain13 have identified various ‘at risk’ groups, in particular the elderly and those with a past history of gastrointestinal problems. These groups have been confirmed in another recent study.14 These data have recently been concisely reviewed.15

In conclusion misoprostol has been shown to prevent NSAID-induced gastric and duodenal damage and certain ‘at risk’ groups of patients can be identified. Studies to address the question whether the use of misoprostol will prevent serious morbidity are underway. Meanwhile the conclusion in a recent review16 regarding this aspect of the use of misoprostol would appear to be scientifically justified — ‘it seems likely (though unproven) that normalization of the gastric mucosa will reduce the likelihood of gastric ulcer complications’.

G.C. Fenn
Associate Director,
Medical Department,
G.D. Searle & Co. Ltd.,
P.O. Box 53,
Lane End Road,
High Wycombe,
Bucks HP12 4HL.

References

Iron deficiency in autoimmune chronic gastritis

Sir,
In a recent report Atrak and Davidson1 concluded that iron deficiency is a common yet neglected complication of long-standing pernicious anaemia, related to chronic iron malabsorption. However, iron deficiency in the context of diffuse antrofundal atrophic gastritis, may present as the initial manifestation of this autoimmune disorder.
Clinical pharmacology and therapeutics.

G. C. Fenn

doi: 10.1136/pgmj.66.778.686

Updated information and services can be found at:
http://pmj.bmj.com/content/66/778/686.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/